Infections and biological therapy in patients with rheumatic diseases

Israel Medical Association Journal

Volumn 18, Issue 3-4, 2016, Pages 164-167

  Atzeni, Fabiola ^a   Batticciotto, Alberto ^b   Masala, Ignazio F ^c   Talotta, Rossella ^b   Benucci, Maurizio ^d   Sarzi Puttini, Piercarlo ^b  

^a IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c SS Trinit Hospital   (Italy)

^d S Giovanni di Dio Hospital   (Italy)

Author keywords

Anti CD20; Anti interleukin 6; Anti tumor necrosis factor (TNF) drugs; Fungal and viral infections; Newer biological drugs

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

CHEMOTHERAPY; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; HEPATITIS B; HEPATITIS C; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; IATROGENIC DISEASE; INFECTION; META ANALYSIS (TOPIC); NOCARDIOSIS; OPPORTUNISTIC INFECTION; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SURGICAL INFECTION; SYSTEMATIC REVIEW (TOPIC); TUBERCULOSIS; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BIOLOGICAL THERAPY; COMBINATION DRUG THERAPY; METABOLISM; PROCEDURES; RHEUMATIC DISEASES; SEVERITY OF ILLNESS INDEX;

ANTIRHEUMATIC AGENTS; BIOLOGICAL THERAPY; CERTOLIZUMAB PEGOL; DRUG THERAPY, COMBINATION; HUMANS; INFECTION; INFLIXIMAB; INTERLEUKIN-6; RHEUMATIC DISEASES; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84963719839     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 2001; 63: 1479-85.
2. Caporali R, Pallavicini FB, Filippini M, et al. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 2009; 8: 274-80.
3. Lahiri M, Dixon WG. Risk of infection with biologic anti-rheumatic therapies in patients with rheumatoid arthritis. Best Pract Res Clin Rheum 2015; 29 (2): 290-305.
4. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls. A population-based study. Arthritis Rheum 2002; 9: 2287-93.
5. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-76.
6. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-12.
7. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011; 50: 124-31.
8. Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011; 70: 1914-20.
9. Atzeni F, Sarzi-Puttini P, Botsios C, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 2012; 12: 225-9.
10. Filippini M, Bazzani C, Favalli EG, et al. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allergy Immunol 2010; 38 (2-3): 90-6.
11. Singh JA, Cameron C, Noorbaloochi S, et al. The risk of serious infection with biologics in treating patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 2015; 386 (9990): 258-65.
12. Keane J, Bresnihan B. Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies. Curr Opin Rheumatol 2008; 20: 443-9.
13. Dittmar M. Human biological research since 2006 at the Christian Albrechts University in Kiel - aging, chronobiology, and high altitude adaptation. Anthropol Anz 2014; 71 (1-2): 143-53.
14. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006; 2: 602-10.
15. Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford) 2014; 53 (10): 1872-85.
16. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human antitumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009; 60: 2272-83.
17. Keystone EC, Combe B, Smolen J, et al. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. Rheumatology (Oxford) 2012; 51: 1628-38.
18. Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68: 797-804.
19. Cantini F, Nannini C, Niccoli L, et al., SAFEBIO (Italian multidisciplinary task force for screening of tuberculosis before and during biologic therapy). Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev 2015; 14: 503-9.
20. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection – United States. MMWR 2010; 59 (RR-5): 1-25.
21. Arkema EV, Jonsson J, Baecklund E, et al. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? Ann Rheum Dis 2015; 74 (6): 1212-17.
22. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor a blockade therapy. Mayo Clin Proc 2008; 83: 181-9.
23. Alvarez B, Arcos J, Fernandez-Guerrero ML. Pulmonary infectious diseases in patients with primary immunodeficiency and those treated with biologic immunomodulating agents. Curr Opin Pulm Med 2011; 17: 172-9.
24. Zisman D, Haddad A, Hashoul S, et al. Hospitalizations of patients treated with anti-tumor necrosis factor-α agents – a retrospective cohort analysis. J Rheumatol 2013; 40: 16-22.
25. Galloway JB, Hyrich KL, Mercer LK, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70: 1810-14.
26. Goh L, Jewell T, Laversuch C, Samanta A. Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence. Rheumatol Int 2012; 32: 5-13.
27. Berthold E, Geborek P, Gulfe A. Continuation of TNF blockade in patients with inflammatory rheumatic disease. An observational study on surgical site infections in 1,596 elective orthopedic and hand surgery procedures. Acta Orthop 2013; 84: 495-501.
28. Davies R, Dixon WG, Watson KD, Lunt M; BSRBR Control Centre Consortium, Symmons DP, Hyrich KL; on behalf of the BSRBR. Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK. Ann Rheum Dis 2013; 72 (3): 461-2.
29. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-12.
30. Che H, Lukas C, Morel J, Combe B. Risk of herpes/herpes zoster during antitumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine 2014; 81: 215-21.
31. Wendling D, Auge B, Bettinger D, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005; 64: 788-9.
32. Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, et al. BIOGEAS Study Group. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011; 90: 359-71.
33. Cantini F, Boccia S, Goletti D, et al. HBV reactivation in patients treated with antitumor necrosis factor-alpha (TNF-α) agents for rheumatic and dermatologic conditions: a systematic review and meta-analysis. Int J Rheumatol 2014; 2014: 926836.
34. Vigano M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther 2012; 12: 193-207.
35. Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004; 51: 800-4.
36. Atzeni F, Sarzi-Puttini P, Mutti A, Bugatti S, Cavagna L, Caporali R. Longterm safety of abatacept in patients with rheumatoid arthritis. Autoimmun Rev 2013; 12: 1115-17.
37. Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 2011; 50: 552-62.
38. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009; 68: 25-32.
39. Vigano ML, Mangia G, Lampertico P. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy. Expert Opin Biol Ther 2014; 14: 1019-31.
40. RABBIT Risk Score of Infections. 2014 November 3. Available from: http://www.biologika-register.de/en/home/risk-score.